Search

everythinglearnresearchcommunity

for

Search:↓

Switching from liquid to foam minoxidil led to hair loss for OP, possibly due to a second shedding cycle. OP experienced allergic reactions to propylene glycol in the liquid form, causing dandruff and itchiness, which improved after switching to foam.

The user reports that using topical Dutasteride has stopped their hair loss, and they are curious about potential side effects and regrowth. They also mention having scalp psoriasis and past SSRI use affecting libido.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation discusses using a lipodermal solution for hair loss, with concerns about side effects from multiple active ingredients. Users mention experiences with minoxidil, finasteride, and dutasteride, noting side effects like brain fog and sexual issues.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A user reports high DHT levels despite taking finasteride and is concerned about inconsistent blood test results. They also take modafinil, vitamin D, and magnesium supplements.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

A user improved their hair health by taking 50,000 IU of vitamin D3 weekly due to a deficiency. Others discussed the potential link between vitamin D and hair growth, with some sharing similar experiences and emphasizing the importance of monitoring vitamin D levels and consulting with doctors.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

Pyrilutamide's effect on sebum production and scalp inflammation is unclear, with users noting no significant changes. Isotretinoin is mentioned as effective for reducing sebum, while Dutasteride and various shampoos have limited impact on oiliness and seborrheic dermatitis.

Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.

The user is concerned about high prolactin levels and low testosterone levels after stopping finasteride for three weeks. They are considering resuming finasteride but are worried it might further increase prolactin levels.

Zinc picolinate and saw palmetto may lower DHT but are less effective than finasteride. Finasteride and minoxidil are preferred treatments, with ketoconazole shampoo as a suggested addition.

User discusses topical liposomal finasteride for hair loss, hoping to avoid breast growth side effect. Conversation includes using minoxidil, fluridil, and dermarolling, and mentions minimal systemic absorption of liposomal finasteride.

Stemoxydine is not a DHT blocker; it works independently to stimulate hair growth. Users discussed its function and clarified it does not block DHT.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

The conversation discusses adjusting the isopropyl alcohol, propylene glycol, and water ratios in a topical finasteride solution for better scalp comfort and less dandruff. The user considers using 20ml IPA, 25ml PG, and 15ml water in a 60ml bottle, moving away from mixing finasteride with topical minoxidil.

Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.

A female user is seeking a DHT blocker without Selenium or Zinc due to hair breakage and is currently using Saw Palmetto, Nature's Bounty Hair, Skin and Nails, Pumpkin seed oil, Dermastamp, and Pura D'or products. She has tried Minoxidil without success and is considering Finasteride but prefers natural options first.

JeremySoCa's DHT level was 29 ng/dl, considered low, and Estradiol was 26.1 pg/dl within the normal range. They are using topical finasteride for hair loss and had a thyroidectomy due to Graves' disease.

The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.